Results 181 to 190 of about 110,204 (324)

Understanding the Variability of Peanut‐Oral Immunotherapy Responses by Multi‐Omics Profiling of Immune Cells

Allergy, Volume 80, Issue 12, Page 3342-3358, December 2025.
This study analyzes molecular drivers of OIT responsiveness. Multi‐omics profiling of peanut‐stimulated PBMCs in a controlled peanut‐OIT trial identifies immune, transcriptomic, and epigenetic changes distinguishing complete responders from incomplete responders. Key findings highlight gastrointestinal immune mechanisms, including extracellular exosome
Aleix Arnau‐Soler, Sarah E. Ashley, Ahla Ghauri, Alexander C. S. N. Jeanrenaud, Ingo Marenholz, Katharina Blumchen, Penelope Cibin, Alisa Iakupova, Norbert Hubner, Kirsten Beyer, Young‐Ae Lee   +10 more
wiley   +1 more source

Cripto-1 Is Elevated In Pediatric Subjects With Eosinophilic Esophagitis [PDF]

, 2014
Lisa Beppu, Arjun Andrew Anilkumar, Richard C. Kurten, Ranjan Dohil, David H. Broide, Seema S. Aceves   +5 more
openalex   +1 more source

Real‐Life Clinical Experience With SQ Grass, Tree, Ragweed, and House Dust Mite Sublingual Immunotherapy Tablets: A Review of Evidence From Non‐Interventional Studies

Allergy, Volume 80, Issue 12, Page 3290-3301, December 2025.
ABSTRACT This review evaluates data from > 12,000 children, adolescents and adults (≥ 4 years) in non‐interventional studies to assess the real‐life effectiveness and safety of SQ sublingual immunotherapy (SLIT)‐tablets for allergic rhinitis (AR).
Oliver Pfaar, Christer Janson, Andreas Horn, André C. Knulst, Pascal Demoly   +4 more
wiley   +1 more source

Reversibility of Endoscopic Features after Treatment for Eosinophilic Esophagitis [PDF]

, 2021
Hong Jin Yoon, Young Hoon Youn, Jun Chul Park, Hyojin Park   +3 more
openalex   +1 more source

SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial

Allergy, Volume 80, Issue 12, Page 3401-3411, December 2025.
Phase III trial investigating the efficacy and safety of SQ HDM SLIT‐tablet in children (5–17 years) with inadequately controlled HDM allergic asthma. Novel paediatric data showing that the safety profile of SQ HDM SLIT‐tablet is similar to that established in adults.
Graham Roberts, Jocelyne Just, Hendrik Nolte, Ole Holm Hels, Andrzej Emeryk, Carmen Vidal   +5 more
wiley   +1 more source

Nonatopic Eosinophilic Esophagitis in an Adult [PDF]

, 2022
Ivanna Ward, Davong D Phrathep, Kevin D Healey, Stefan Anthony, Michael Herman   +4 more
openalex   +1 more source

Antimicrobial prescribing guidelines for horses in Australia

Australian Veterinary Journal, Volume 103, Issue 12, Page 781-889, December 2025.
The growing problem of antimicrobial resistance also affects equine veterinarians with increasing frequency. Antimicrobial stewardship and responsible prescribing are essential for a future in which effective antimicrobials are available, as it is unlikely that new antimicrobials will become available for use in horses.
L Hardefeldt, K Thomas, S Page, J Norris, G Browning, C El Hage, A Stewart, J Gilkerson, G Muscatello, D Verwilghen, G van Galen, J Bauquier, R Cuming, B Reynolds, C Whittaker, E Wilkes, J Clulow, C Burden, L Begg   +18 more
wiley   +1 more source

Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis

Pharmaceuticals
Eosinophilic Esophagitis is an antigen-mediated inflammatory disease characterized by thickening of the esophageal wall, leading to dysphagia, vomiting, reflux, and abdominal pain. This disease can be treated with a therapeutic approach ranging from diet
Antonio Spennacchio, Antonio Lopalco, Giuseppe Francesco Racaniello, Annalisa Cutrignelli, Flavia Maria la Forgia, Sergio Fontana, Fernanda Cristofori, Ruggiero Francavilla, Angela Assunta Lopedota, Nunzio Denora   +9 more
doaj   +1 more source

Gastric biopsies with prominent eosinophils: Clinicopathologic features and response to therapy

Histopathology, Volume 87, Issue 6, Page 880-893, December 2025.
The use of the term ‘histologic eosinophilic gastritis’ (EoG) has been proposed for cases with ≥30 eosinophils/high power field (HPF) in five separate HPF and with no known associated causes of eosinophilia; however, these criteria can miss cases with clinically significant eosinophilia and our study results argue against using this term for pathology ...
Nigar Anjuman Khurram, Sanjay Kakar, Dana Balitzer   +2 more
wiley   +1 more source

Assessment Of Psychiatric Comorbities In Pediatric Patients With Eosinophilic Esophagitis [PDF]

, 2019
Aishwarya Navalpakam, Ashley Kroon Van Diest, Kristen R. Hoskinson, John Russo, Elizabeth A. Erwin   +4 more
openalex   +1 more source